DOJ Moves to Reward Health Care Companies That Report Their Own Fraud

For the people who rely on Medicare and Medicaid, fraud isn't an abstract line item. It's the reason a wheelchair claim gets denied, the reason a clinic overbills for a service nobody received, the reason taxpayer dollars meant for care get siphoned into someone else's pocket. The Department of Justice wants health care executives to understand that distinction clearly, and its latest message to them is blunt: don't be the next Theranos.

That warning came from Jacob Foster, deputy assistant attorney general in the DOJ's National Fraud Enforcement division, speaking Thursday at the STAT Summit in Boston. Foster oversees the unit responsible for investigating health care fraud, and he laid out a shift in strategy that's as much about incentives as it is about punishment. As the Trump administration ramps up its broader fight against Medicare and Medicaid fraud, it's also widening its net to catch corporate wrongdoing across the health sector, including a recent expansion that added pharmaceutical companies to the list of priority targets.

The core of the new approach is simple in concept, even if it's complicated in practice. The DOJ wants to make it easier, and more attractive, for companies to report their own potential criminal conduct before investigators come knocking. Think of it like a homeowner who notices a gas leak. Call it in yourself, and you get help fixing it. Wait for someone else to smell smoke, and you're facing a very different conversation with the fire department.

Self-Disclosure as a Compliance Strategy

Self-disclosure programs aren't a new idea in federal enforcement, but the emphasis Foster described signals how central they've become to the DOJ's health care fraud strategy under the current administration. The logic is straightforward: companies have information investigators often don't. Internal audits, compliance reviews, and employee tips can surface problems long before a government subpoena ever lands on a general counsel's desk. If firms believe that coming forward early will result in meaningfully better treatment than getting caught later, more of them are likely to do it.

That's the theory, anyway. In practice, these programs only work if the incentives are real and companies trust that cooperation will actually be rewarded with reduced penalties, rather than just faster prosecution. Health care compliance officers have spent years navigating a patchwork of disclosure obligations, and skepticism about whether self-reporting genuinely pays off has been a persistent obstacle. The DOJ's renewed push suggests officials are trying to close that trust gap, making self-disclosure not just permissible but genuinely advantageous.

Whistleblowing sits alongside self-disclosure as a second pillar of the strategy. Encouraging employees inside health care organizations, the people closest to billing practices, clinical decisions, and internal communications, to come forward when they see wrongdoing adds another layer of oversight that government investigators simply can't replicate from outside. For decades, whistleblower cases brought under the False Claims Act have been one of the most effective tools for uncovering Medicare and Medicaid fraud, often resulting in massive settlements and returning billions of dollars to federal health programs. Strengthening that pipeline, rather than relying solely on external audits and investigations, could meaningfully increase the government's reach without requiring a proportional increase in investigative staff.

The reference to Theranos is worth sitting with. The blood-testing startup became a cautionary tale not just for the fraud itself, but for how long it went undetected and how much damage accumulated before regulators and prosecutors caught up. Foster's invocation of that case at a health care summit wasn't incidental. It was a pointed reminder that corporate fraud in health care doesn't just cost money. It erodes trust in the systems patients depend on for accurate diagnoses, reliable treatments, and honest billing.

This expansion into pharma and broader corporate accountability also reflects a recognition that health care fraud doesn't live in one corner of the industry. Billing schemes at a single clinic are one kind of problem. Systemic misrepresentation by a major drug manufacturer or device maker is another, with the potential to affect far more patients and far more taxpayer dollars. By widening its priorities, the DOJ seems to be acknowledging that fraud enforcement focused narrowly on fraudulent claims misses a lot of the bigger, more consequential wrongdoing.

Still, encouraging self-disclosure raises its own set of tensions. Critics of leniency-based enforcement models sometimes worry that generous treatment for companies that confess can look, from the outside, like a pass for bad behavior, especially if penalties end up lighter than the harm caused. Supporters counter that the alternative, relying entirely on whistleblowers and investigators to uncover every instance of fraud, is slower, more resource intensive, and ultimately catches less wrongdoing overall. There's no perfect answer here, just tradeoffs that regulators are trying to balance.

Why It Matters

The stakes extend well beyond corporate boardrooms and compliance departments. Medicare and Medicaid serve tens of millions of Americans, many of them older adults, people with disabilities, and low-income families who have few alternatives if the system fails them. Every dollar lost to fraud is a dollar not spent on actual care, and every delayed detection means more time for harm to compound, whether that's inflated billing draining program funds or, as in cases like Theranos, patients receiving unreliable medical information that shapes real health decisions.

A policy that genuinely encourages earlier self-reporting could shrink that window of harm. Catching fraud sooner, even through imperfect leniency deals, generally beats catching it years later after it has metastasized across thousands of patients or billions of dollars in false claims. But the success of this approach will depend heavily on execution: how consistently the DOJ applies its promised leniency, how well whistleblower protections hold up in practice, and whether companies genuinely believe disclosure beats concealment. For now, the message from Washington is clear. The agency would rather have executives walk through its door voluntarily than send investigators to knock it down.